Neoadjuvant docetaxel, oxaliplatin plus capecitabine versus oxaliplatin plus capecitabine phase III randomized controlled clinical trial for patients with locally advanced gastric adenocarcinoma: long-term results of a randomised controlled trial.
International journal of surgery (London, England)（2023）
摘要
The neoadjuvant DOX regimen has shown the potential to increase the pCR rate and improve the prognosis of patients with advanced gastric cancer who are under 60 years old.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要